738P Quality-adjusted time without symptom or toxicity (QA-TWiST) and quality-adjusted progression-free survival (QA-PFS) of first-line (1L) maintenance niraparib in patients with advanced ovarian cancer (OC): Results from the PRIMA trial

Authors :: A. González Martín
Sileny Han
T. Woodward
Carol Hawkes
Andrés Redondo
Divya Gupta
Charles K. Anderson
Reshma Shah
Bradley J. Monk
M-P. Barretina-Ginesta
Sophie Abadie-Lacourtoisie
A. Auranen
Bhavana Pothuri
David M. O'Malley
Elena-Ioana Braicu
Domenica Lorusso
N.G. Cloven
N. Kebede
Dana M. Chase
Amnon Amit
Source :: Annals of Oncology. 32:S736-S737
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Oncology
medicine.medical_specialty
Advanced ovarian cancer
business.industry
media_common.quotation_subject
First line
Hematology
Internal medicine
Toxicity
medicine
Quality (business)
In patient
Progression-free survival
business
media_common

Tools